Klippel-Trenaunay syndrome
Clinical trials for Klippel-Trenaunay syndrome explained in plain language.
Never miss a new study
Get alerted when new Klippel-Trenaunay syndrome trials appear
Sign up with your email to follow new studies for Klippel-Trenaunay syndrome, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill could shrink abnormal vessels in rare childhood disorders
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called KP-001 in 150 people aged 2 and older with venous malformations, lymphatic malformations, or KTS/CLOVES syndrome. Participants receive either KP-001 or a placebo for 24 weeks, then everyone gets the drug for another 28 weeks. The goal …
Matched conditions: KLIPPEL-TRENAUNAY SYNDROME
Phase 3 • Sponsor: Kaken Pharmaceutical • Aim: Disease control
Last updated Sep 21, 2026 15:00 UTC
-
New drug targets root cause of rare overgrowth syndromes
Disease control Recruiting nowThis Phase 2 study tests an oral drug called RLY-2608 in adults and children with overgrowth conditions (like CLOVES or Klippel-Trenaunay syndrome) caused by PIK3CA gene mutations. The drug is designed to block the faulty protein driving abnormal tissue growth. The trial will enr…
Matched conditions: KLIPPEL-TRENAUNAY SYNDROME
Phase 2 • Sponsor: Relay Therapeutics, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Scientists launch global effort to unravel mysteries of rare lymphatic diseases
Knowledge-focused Recruiting nowThis study is creating a registry of up to 1,000 people with rare lymphatic system disorders. Researchers will collect information from medical records and yearly surveys to understand how these diseases progress, what treatments are used, and how they affect quality of life. The…
Matched conditions: KLIPPEL-TRENAUNAY SYNDROME
Sponsor: Boston Children's Hospital • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC